Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Q: What are the significant segments operating in the market?

Market is segmented on the basis. Read More

Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Report ID : 78402
Published On: Apr, 2021
Pages: 156
Pharmaceuticals and Healthcare

Buy @ $3500

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) size is estimated to be USD 6884.5 million in 2026 from USD 5330.8 million in 2020, with a change XX% between 2020 and 2021. The global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size is expected to grow at a CAGR of 6.6% for the next five years.

Market segmentation

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

PCR

In-situ Hybridization

Immunohistochemistry

Sequencing

Others

Market segment by Application, can be divided into

Oncology

Neurological Disorders

Cardiovascular Disease

Immunological Disorders

Others

Market segment by players, this report covers

Qiagen NV

GE Healthcare

Agilent Technologies

F Hoffman La Roche

Foundation Medicine

Thermo Fisher Scientific Inc.

Leica Biosystems Nussloch GmBH

Pfizer

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx), with revenue, gross margin and global market share of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) from 2019 to 2021.

Chapter 3, the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market forecast, by regions, type and application, with revenue, from 2021 to 2026.

Chapter 11 and 12, to describe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) research findings and conclusion, appendix and data source.

Frequently Asked Questions

What is scope of the report?

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

What are the significant segments operating in the market?

Market is segmented on the basis:

By Type
By Application
By Region
By Country
By Manufacturer

What are the vital market dynamics?

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

What does a company profile includes?

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)

1.2 Classification of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by Type

1.2.1 Overview: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Type in 2020

1.2.3 PCR

1.2.4 In-situ Hybridization

1.2.5 Immunohistochemistry

1.2.6 Sequencing

1.2.7 Others

1.3 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market by Application

1.3.1 Overview: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Oncology

1.3.3 Neurological Disorders

1.3.4 Cardiovascular Disease

1.3.5 Immunological Disorders

1.3.6 Others

1.4 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size & Forecast

1.5 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast by Region

1.5.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region, (2016-2021)

1.5.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2016-2026)

1.5.4 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2016-2026)

1.5.6 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers

1.6.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints

1.6.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Trends Analysis

2 Company Profiles

2.1 Qiagen NV

2.1.1 Qiagen NV Details

2.1.2 Qiagen NV Major Business

2.1.3 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

2.1.4 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Qiagen NV Recent Developments and Future Plans

2.2 GE Healthcare

2.2.1 GE Healthcare Details

2.2.2 GE Healthcare Major Business

2.2.3 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

2.2.4 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 GE Healthcare Recent Developments and Future Plans

2.3 Agilent Technologies

2.3.1 Agilent Technologies Details

2.3.2 Agilent Technologies Major Business

2.3.3 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

2.3.4 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Agilent Technologies Recent Developments and Future Plans

2.4 F Hoffman La Roche

2.4.1 F Hoffman La Roche Details

2.4.2 F Hoffman La Roche Major Business

2.4.3 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

2.4.4 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 F Hoffman La Roche Recent Developments and Future Plans

2.5 Foundation Medicine

2.5.1 Foundation Medicine Details

2.5.2 Foundation Medicine Major Business

2.5.3 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

2.5.4 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Foundation Medicine Recent Developments and Future Plans

2.6 Thermo Fisher Scientific Inc.

2.6.1 Thermo Fisher Scientific Inc. Details

2.6.2 Thermo Fisher Scientific Inc. Major Business

2.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

2.6.4 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Thermo Fisher Scientific Inc. Recent Developments and Future Plans

2.7 Leica Biosystems Nussloch GmBH

2.7.1 Leica Biosystems Nussloch GmBH Details

2.7.2 Leica Biosystems Nussloch GmBH Major Business

2.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

2.7.4 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Leica Biosystems Nussloch GmBH Recent Developments and Future Plans

2.8 Pfizer

2.8.1 Pfizer Details

2.8.2 Pfizer Major Business

2.8.3 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

2.8.4 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Pfizer Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Market Share

3.2.2 Top 10 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Market Share

3.2.3 Market Competition Trend

3.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Market Share by Type (2016-2021)

4.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Application (2016-2021)

5.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2026)

6.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2026)

6.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country

6.3.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2026)

6.3.2 United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

6.3.3 Canada Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

6.3.4 Mexico Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2026)

7.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2026)

7.3 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country

7.3.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2026)

7.3.2 Germany Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

7.3.3 France Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

7.3.5 Russia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

7.3.6 Italy Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2026)

8.2 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2026)

8.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region

8.3.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Region (2016-2026)

8.3.2 China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

8.3.3 Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

8.3.4 South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

8.3.5 India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

8.3.7 Australia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2026)

9.2 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2026)

9.3 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country

9.3.1 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2026)

9.3.2 Brazil Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

9.3.3 Argentina Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2026)

10.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2026)

10.3 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country

10.3.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2026)

10.3.2 Turkey Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

10.3.4 UAE Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) by Region (2016-2021)

Table 5. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Region (2021-2026)

Table 6. Qiagen NV Corporate Information, Head Office, and Major Competitors

Table 7. Qiagen NV Major Business

Table 8. Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

Table 9. Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. GE Healthcare Corporate Information, Head Office, and Major Competitors

Table 11. GE Healthcare Major Business

Table 12. GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

Table 13. GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Agilent Technologies Corporate Information, Head Office, and Major Competitors

Table 15. Agilent Technologies Major Business

Table 16. Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

Table 17. Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. F Hoffman La Roche Corporate Information, Head Office, and Major Competitors

Table 19. F Hoffman La Roche Major Business

Table 20. F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

Table 21. F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Foundation Medicine Corporate Information, Head Office, and Major Competitors

Table 23. Foundation Medicine Major Business

Table 24. Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

Table 25. Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Thermo Fisher Scientific Inc. Corporate Information, Head Office, and Major Competitors

Table 27. Thermo Fisher Scientific Inc. Major Business

Table 28. Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

Table 29. Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Leica Biosystems Nussloch GmBH Corporate Information, Head Office, and Major Competitors

Table 31. Leica Biosystems Nussloch GmBH Major Business

Table 32. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

Table 33. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Pfizer Corporate Information, Head Office, and Major Competitors

Table 35. Pfizer Major Business

Table 36. Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions

Table 37. Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) by Players (2019-2021)

Table 39. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Players (2019-2021)

Table 40. Breakdown of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by Company Type (Tier 1, Tier 2 and Tier 3)

Table 41. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Head Office, Products and Services Provided

Table 42. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Mergers & Acquisitions in the Past Five Years

Table 43. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) New Entrants and Expansion Plans

Table 44. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) by Type (2016-2021)

Table 45. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Type (2016-2021)

Table 46. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Forecast by Type (2021-2026)

Table 47. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021)

Table 48. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Forecast by Application (2021-2026)

Table 49. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2021) & (USD Million)

Table 50. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2021-2026) & (USD Million)

Table 51. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021) & (USD Million)

Table 52. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2021-2026) & (USD Million)

Table 53. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2021) & (USD Million)

Table 54. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2021-2026) & (USD Million)

Table 55. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2021) & (USD Million)

Table 56. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2021-2026) & (USD Million)

Table 57. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021) & (USD Million)

Table 58. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2021-2026) & (USD Million)

Table 59. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2021) & (USD Million)

Table 60. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2021-2026) & (USD Million)

Table 61. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2021) & (USD Million)

Table 62. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2021-2026) & (USD Million)

Table 63. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021) & (USD Million)

Table 64. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2021-2026) & (USD Million)

Table 65. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Region (2016-2021) & (USD Million)

Table 66. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Region (2021-2026) & (USD Million)

Table 67. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2021) & (USD Million)

Table 68. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2021-2026) & (USD Million)

Table 69. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021) & (USD Million)

Table 70. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2021-2026) & (USD Million)

Table 71. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2021) & (USD Million)

Table 72. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2021-2026) & (USD Million)

Table 73. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2016-2021) & (USD Million)

Table 74. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Type (2021-2026) & (USD Million)

Table 75. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2016-2021) & (USD Million)

Table 76. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Application (2021-2026) & (USD Million)

Table 77. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2016-2021) & (USD Million)

Table 78. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Picture

Figure 2. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Type in 2020

Figure 3. PCR

Figure 4. In-situ Hybridization

Figure 5. Immunohistochemistry

Figure 6. Sequencing

Figure 7. Others

Figure 8. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Application in 2020

Figure 9. Oncology Picture

Figure 10. Neurological Disorders Picture

Figure 11. Cardiovascular Disease Picture

Figure 12. Immunological Disorders Picture

Figure 13. Others Picture

Figure 14. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 15. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Forecast (2016-2026) & (USD Million)

Figure 16. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Region (2016-2026)

Figure 17. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Region in 2020

Figure 18. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2016-2026)

Figure 21. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2016-2026)

Figure 22. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2016-2026)

Figure 23. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers

Figure 24. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints

Figure 25. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Trends

Figure 26. Qiagen NV Recent Developments and Future Plans

Figure 27. GE Healthcare Recent Developments and Future Plans

Figure 28. Agilent Technologies Recent Developments and Future Plans

Figure 29. F Hoffman La Roche Recent Developments and Future Plans

Figure 30. Foundation Medicine Recent Developments and Future Plans

Figure 31. Thermo Fisher Scientific Inc. Recent Developments and Future Plans

Figure 32. Leica Biosystems Nussloch GmBH Recent Developments and Future Plans

Figure 33. Pfizer Recent Developments and Future Plans

Figure 34. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Players in 2020

Figure 35. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 36. Global Top 3 Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share in 2020

Figure 37. Global Top 10 Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share in 2020

Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 39. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Type in 2020

Figure 40. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share Forecast by Type (2021-2026)

Figure 41. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Application in 2020

Figure 42. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share Forecast by Application (2021-2026)

Figure 43. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Type (2016-2026)

Figure 44. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Application (2016-2026)

Figure 45. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Country (2016-2026)

Figure 46. United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 47. Canada Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 48. Mexico Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 49. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Type (2016-2026)

Figure 50. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Application (2016-2026)

Figure 51. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Country (2016-2026)

Figure 52. Germany Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. France Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. United Kingdom Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. Russia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 56. Italy Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 57. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Type (2016-2026)

Figure 58. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Application (2016-2026)

Figure 59. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Region (2016-2026)

Figure 60. China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 65. Australia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 66. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Type (2016-2026)

Figure 67. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Application (2016-2026)

Figure 68. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Country (2016-2026)

Figure 69. Brazil Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 70. Argentina Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Type (2016-2026)

Figure 72. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share by Application (2016-2026)

Figure 73. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Country (2016-2026)

Figure 74. Turkey Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 75. Saudi Arabia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 76. UAE Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 77. Methodology

Figure 78. Research Process and Data Source